Loading stock data…
$117.66+8.03 (+7.33%)
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
Halozyme Therapeutics, Inc. in the Healthcare sector is trading at $117.64 with a market capitalization of $12.3B. Wall Street consensus targets $104.89 (9 analysts), implying a -10.8% move over the next 12 months. The stock is currently near its 52-week high of $119.21, remaining 46.9% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $481.00M↑ | $376.71M↓ | $451.77M↑ | $354.26M↑ | $325.72M |
| Gross Profit | $401.83M↑ | $297.47M↓ | $373.00M↑ | $299.02M↑ | $279.36M |
| Operating Income | $287.65M↑ | $184.52M↓ | $240.70M↑ | $217.92M↑ | $202.44M |
| Net Income | $229.91M↑ | $150.05M↑ | -$141.59M↓ | $175.22M↑ | $165.16M |
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the pate...